- Home
- INMB vs ATNM Comparison
INMB vs ATNM Comparison
Compare INMB & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ATNM
- Stock Information
- Founded
- INMB 2015
- ATNM 2000
- Country
- INMB United States
- ATNM United States
- Employees
- INMB N/A
- ATNM N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ATNM Health Care
- Exchange
- INMB Nasdaq
- ATNM Nasdaq
- Market Cap
- INMB 55.0M
- ATNM 50.2M
- IPO Year
- INMB 2019
- ATNM N/A
- Fundamental
- Price
- INMB $1.98
- ATNM $1.58
- Analyst Decision
- INMB Buy
- ATNM Strong Buy
- Analyst Count
- INMB 4
- ATNM 2
- Target Price
- INMB $9.53
- ATNM $4.50
- AVG Volume (30 Days)
- INMB 564.4K
- ATNM 116.8K
- Earning Date
- INMB 10-30-2025
- ATNM 11-13-2025
- Dividend Yield
- INMB N/A
- ATNM N/A
- EPS Growth
- INMB N/A
- ATNM N/A
- EPS
- INMB N/A
- ATNM N/A
- Revenue
- INMB $50,000.00
- ATNM N/A
- Revenue This Year
- INMB $142.83
- ATNM N/A
- Revenue Next Year
- INMB $14,780.90
- ATNM N/A
- P/E Ratio
- INMB N/A
- ATNM N/A
- Revenue Growth
- INMB N/A
- ATNM N/A
- 52 Week Low
- INMB $1.71
- ATNM $1.03
- 52 Week High
- INMB $11.64
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- INMB 41.99
- ATNM 42.17
- Support Level
- INMB $1.92
- ATNM $1.56
- Resistance Level
- INMB $2.16
- ATNM $1.64
- Average True Range (ATR)
- INMB 0.11
- ATNM 0.06
- MACD
- INMB 0.03
- ATNM -0.01
- Stochastic Oscillator
- INMB 42.86
- ATNM 6.67
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.